CClinicalTrials.gg
Not yet recruitingNCT06097598IrritablebowelUpdated Oct 24, 2023

Prevalence of Irritable Bowel Syndrome in Medical Students Africa

An observational study in Faculty of Medicine, sponsored by Assiut University. Not yet recruiting. Open to participants aged Up to 27 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 6 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
1,131
Ages
Up to 27 Years
Sex
All
01

Study summary

The aim of the present study was to assess the prevalence of IBS among medical students in the Middle East and North Africa and to investigate the sociodemographic, lifestyle, and clinical factors associated with IBS. A better understanding of IBS correlates is expected to improve our therapeutic approach to IBS in this population.

Read the detailed description

Irritable bowel syndrome (IBS) is a multifactorial chronic disease characterized with functional gastrointestinal disorder which affects the quality of life of the patient. Until now the pathophysiology of IBS was not completely understood but it has been related to multiple mechanisms like: visceral hypersensitivity, Brain-gut axis, post infectious inflammation and genetic abnormalities.(1) Many demographic and environmental factors are considered risk factors for the condition like: sex, age, BMI, social status and life style(2). IBS outspreaded all over the world varying between 14.7% to 16.5% in east Asian countries(3,4). As IBS is diagnosed mainly clinically, many scales have been developed to provide the best sensitivity for diagnosing the condition. The recent common criteria for diagnosing are ROME III and ROME VI. A meta-analysis conducted by Oka et al the pooled prevalence of IBS in 53 surveys that used the Rome III criteria from 38 countries was 9.2% (95% CI 7.6-10.8; I2 = 99.7%). Contrary, the pooled IBS prevalence among the 6 surveys that used the Rome IV criteria from 34 countries was 3.8% (95% CI 3.1-4.5; I2 = 96.6%)(5). The different prevalence rates are probably justified by the multifactorial nature of the disease and the various social status and environments from a country to another. However, there wasn't enough studies could define the prevalence of IBS among middle-eastern countries. The prevalence of IBS varies depending on socioeconomic factors, sex, and age. University students in the Middle East and North Africa are affected by many Lifestyle factors that participate in IBS by one way or another such as unhealthy eating habits (junk or fast food), cigarette smoking, physical inactivity and the fact that they're living low-income countries. IBS has also been associated with psychological factors such as stress, depression, and anxiety. Additionally, as their young age genetic factors and positive family history are implicated. Medical students, are more likely exposed to IBS risk factors as they have limited access to healthy meals, financial constraints, and a excessive exposure to stress secondary to their exceedingly demanding education and frequent examinations. Thus, they are more probably to develop IBS than other population subgroups.

02

Conditions studied

  • Faculty of Medicine
03

In context

Irritable Bowel Syndrome

1,062 studies on the registry are indexed under Irritable Bowel Syndrome; 190 are open to participants now.

This study's planned enrollment of 1,131 is above the median of 150 across 178 observational studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 27 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Medical students enrolled in from medical schools located in the Middle East and North Africa.

Inclusion criteria

  • Medical students enrolled in from medical schools located in the Middle East and North Africa.

Exclusion criteria

Exclusion Criteria:

  • 1- History of significant comorbidities 2- Participants with definite or suspected history of inflammatory bowel disease, celiac disease, Lactose intolerance or peptic ulcer disease. 3- Psychiatric patients or patients on antidepressant treatment or using psychotropic drugs affecting their cognitive ability.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
1,131 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Describe the prevalence of IBS among medical students

    assess the prevalence of IBS among medical students in the Middle East and North Africa and to investigate the sociodemographic, Page 3 of lifestyle, and clinical factors associated with IBS. A better understanding of IBS correlates is expected to improve our therapeutic approach to IBS in this population.

    Time frame: 6 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012 Oct 25;367(17):1626-35. doi: 10.1056/NEJMra1207068. No abstract available. PubMed 23094724 ↗
  • Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):473-486. doi: 10.1038/s41575-020-0286-8. Epub 2020 Apr 15. PubMed 32296140 ↗
  • Seger S, Nasharuddin NNB, Fernandez SL, Yunus SRBM, Shun NTM, Agarwal P, Burud I. Prevalence and factors associated with irritable bowel syndrome among medical students in a Malaysian private university: a cross sectional study. Pan Afr Med J. 2020 Oct 13;37:151. doi: 10.11604/pamj.2020.37.151.21716. eCollection 2020. PubMed 33425184 ↗
  • Basandra S, Bajaj D. Epidemiology of Dyspepsia and Irritable Bowel Syndrome (IBS) in Medical Students of Northern India. J Clin Diagn Res. 2014 Dec;8(12):JC13-6. doi: 10.7860/JCDR/2014/10710.5318. Epub 2014 Dec 5. PubMed 25653974 ↗
  • Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20. Erratum In: Lancet Gastroenterol Hepatol. 2020 Dec;5(12):e8. doi: 10.1016/S2468-1253(20)30349-6. PubMed 32702295 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06097598
Lead sponsor
Assiut University
Collaborators
AsyutUniversity
Responsible party
Zeinab Galal Eldeen Abdelhamid (Demonstrator, Assiut University) — Principal investigator
First posted
Oct 24, 2023
Start date
Oct 20, 2023 (estimated)
Primary completion
Mar 10, 2024 (estimated)
Completion
Oct 10, 2024 (estimated)
Last update
Oct 24, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion